Crossmark

Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1007/s00066-024-02347-y

Published Online: 2025-01-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lv, Xiaoyan

Wang, Shuai

Zhang, Wencheng

Pang, Qingsong

Lin, Qiang

Wu, Yajing

Hui, Zhouguang

Liu, Yueping

Cheng, Yunjie

Liu, Qing

Wang, Jun https://orcid.org/0000-0002-9733-1433
Funding

Funding for this research was provided by:

National Key R&D Program of China (2023YFC2413900)

Hebei Clinical Research Center for Radiation Oncology (2057702D)

Natural Science Foundation of Hebei Province (H2023206346; H2021206293; H2020206348)
License Information

Text and Data Mining valid from 2025-01-14

Version of Record valid from 2025-01-14
More Information

Article History

Received: 11 July 2024

Accepted: 1 December 2024

First Online: 14 January 2025

Conflict of interest

: X. Lv, S. Wang, W. Zhang, Q. Pang, Q. Lin, Y. Wu, Z. Hui, Y. Liu, Y. Cheng, Q. Liu and J. Wang declare that they have no competing interests.

Document is current

Any future updates will be listed below